BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36434173)

  • 1. Effects of polybrene and retronectin as transduction enhancers on the development and phenotypic characteristics of VHH-based CD19-redirected CAR T cells: a comparative investigation.
    Nasiri F; Muhammadnejad S; Rahbarizadeh F
    Clin Exp Med; 2023 Oct; 23(6):2535-2549. PubMed ID: 36434173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
    Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells.
    Rajabzadeh A; Hamidieh AA; Rahbarizadeh F
    BMC Mol Cell Biol; 2021 Nov; 22(1):57. PubMed ID: 34814824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
    Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
    Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimization of CAR-T cell culture system and lentivirus transduction conditions].
    Wang H; Pan J; Jiang D; Qu Y; Li Y; Li G; Chu Y; Zhang X; Xu G
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 May; 36(5):390-397. PubMed ID: 32696750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.
    Sawaisorn P; Atjanasuppat K; Uaesoontrachoon K; Rattananon P; Treesuppharat W; Hongeng S; Anurathapan U
    PLoS One; 2023; 18(2):e0281735. PubMed ID: 36780428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
    Sakai O; Igase M; Mizuno T
    Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.
    Sun J; Huye LE; Lapteva N; Mamonkin M; Hiregange M; Ballard B; Dakhova O; Raghavan D; Durett AG; Perna SK; Omer B; Rollins LA; Leen AM; Vera JF; Dotti G; Gee AP; Brenner MK; Myers DG; Rooney CM
    J Immunother Cancer; 2015; 3():5. PubMed ID: 25734008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplified process for the production of anti-CD19-CAR-engineered T cells.
    Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
    Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.
    Agarwalla P; Ogunnaike EA; Ahn S; Ligler FS; Dotti G; Brudno Y
    Adv Healthc Mater; 2020 Jul; 9(14):e2000275. PubMed ID: 32592454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
    Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
    Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.
    Bunse M; Höpken UE
    Methods Mol Biol; 2022; 2521():67-83. PubMed ID: 35732993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.